Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H27N3O4S |
Molecular Weight | 429.532 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(OCC2COC(C)(C)OC2)C(C)=C(C[S@@+]([O-])C3=NC4=C(N3)C=CC=C4)N=C1
InChI
InChIKey=DWDKHTXMLSZGDL-SSEXGKCCSA-N
InChI=1S/C22H27N3O4S/c1-14-9-23-19(13-30(26)21-24-17-7-5-6-8-18(17)25-21)15(2)20(14)27-10-16-11-28-22(3,4)29-12-16/h5-9,16H,10-13H2,1-4H3,(H,24,25)/t30-/m1/s1
Molecular Formula | C22H27N3O4S |
Molecular Weight | 429.532 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion. | 2010 Aug |
|
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. | 2018 |
|
Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. | 2018 Apr |
|
Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers. | 2018 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30038671
Once a day within about 30 minutes after breakfast 10, 20, or 40 mg for 8 weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:15:32 GMT 2023
by
admin
on
Sat Dec 16 02:15:32 GMT 2023
|
Record UNII |
MIR2G6L61B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
17747247
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
10426
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
MIR2G6L61B
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
C174711
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
DTXSID50241865
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
955095-45-1
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
300000034083
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY | |||
|
Azeloprazole
Created by
admin on Sat Dec 16 02:15:32 GMT 2023 , Edited by admin on Sat Dec 16 02:15:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|